Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.

González-Oria MC, Márquez-Coello M, Girón-Ortega JA, Argente J, Moya M, Girón-González JA.

J Neuroimmune Pharmacol. 2019 Jan 16. doi: 10.1007/s11481-018-09832-z. [Epub ahead of print]

PMID:
30649665
2.

Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon-β therapy.

Cosentino M, Zaffaroni M, Trojano M, Giorelli M, Pica C, Rasini E, Bombelli R, Ferrari M, Ghezzi A, Comi G, Livrea P, Lecchini S, Marino F.

Neuroimmunomodulation. 2012;19(5):283-92. doi: 10.1159/000336981. Epub 2012 Apr 3.

PMID:
22472872
3.

The Th17/Treg ratio, IL-1RA and sCD14 levels in primary HIV infection predict the T-cell activation set point in the absence of systemic microbial translocation.

Chevalier MF, Petitjean G, Dunyach-Rémy C, Didier C, Girard PM, Manea ME, Campa P, Meyer L, Rouzioux C, Lavigne JP, Barré-Sinoussi F, Scott-Algara D, Weiss L.

PLoS Pathog. 2013;9(6):e1003453. doi: 10.1371/journal.ppat.1003453. Epub 2013 Jun 20.

4.

Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.

Mitsdoerffer M, Schreiner B, Kieseier BC, Neuhaus O, Dichgans J, Hartung HP, Weller M, Wiendl H.

J Neuroimmunol. 2005 Feb;159(1-2):155-64. Epub 2004 Dec 28.

PMID:
15652415
5.

Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10years in responder multiple sclerosis patients.

Spadaro M, Montarolo F, Perga S, Martire S, Brescia F, Malucchi S, Bertolotto A.

Clin Immunol. 2017 Aug;181:83-88. doi: 10.1016/j.clim.2017.06.006. Epub 2017 Jun 19.

PMID:
28642148
7.

Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis.

Putheti P, Soderstrom M, Link H, Huang YM.

J Neuroimmunol. 2003 Nov;144(1-2):125-31.

PMID:
14597106
8.

Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate.

Carrieri PB, Carbone F, Perna F, Bruzzese D, La Rocca C, Galgani M, Montella S, Petracca M, Florio C, Maniscalco GT, Spitaleri DL, Iuliano G, Tedeschi G, Della Corte M, Bonavita S, Matarese G.

Metabolism. 2015 Sep;64(9):1112-21. doi: 10.1016/j.metabol.2015.05.001. Epub 2015 May 8.

PMID:
25986733
9.

Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.

Ochi H, Feng-Jun M, Osoegawa M, Minohara M, Murai H, Taniwaki T, Kira J.

J Neurol Sci. 2004 Jul 15;222(1-2):65-73.

PMID:
15240198
10.

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pellegrini F, Wiendl H, Belachew S, Hyde R, Verheul F, Lugaresi A, Havrdová E, Horáková D, Grammond P, Duquette P, Prat A, Iuliano G, Terzi M, Izquierdo G, Hupperts RM, Boz C, Pucci E, Giuliani G, Sola P, Spitaleri DL, Lechner-Scott J, Bergamaschi R, Grand'Maison F, Granella F, Kappos L, Trojano M, Butzkueven H.

Neurol Clin Pract. 2016 Apr;6(2):102-115.

11.

Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis.

Zafranskaya M, Oschmann P, Engel R, Weishaupt A, van Noort JM, Jomaa H, Eberl M.

Immunology. 2007 May;121(1):29-39. Epub 2006 Dec 18.

12.
13.

Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.

Hamamcioglu K, Reder AT.

Mult Scler. 2007 May;13(4):459-70. Epub 2007 Feb 9.

PMID:
17463069
14.

Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis.

Hussien Y, Sanna A, Söderström M, Link H, Huang YM.

J Neuroimmunol. 2001 Dec 3;121(1-2):102-10.

PMID:
11730946
15.

Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-beta 1b-treated multiple sclerosis patients.

Ferrarini AM, Sivieri S, Buttarello M, Facchinetti A, Perini P, Gallo P.

Mult Scler. 1998 Jun;4(3):174-7.

PMID:
9762669
16.

Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing-remitting multiple sclerosis patients.

Berthelot L, Miqueu P, Pettré S, Guillet M, Moynard J, Wiertlewski S, Lefrère F, Brouard S, Soulillou JP, Laplaud DA.

Clin Immunol. 2010 Apr;135(1):33-42. doi: 10.1016/j.clim.2009.12.006. Epub 2010 Feb 8.

PMID:
20116333
17.

Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations.

Praksova P, Stourac P, Bednarik J, Vlckova E, Mikulkova Z, Michalek J.

J Neurol Sci. 2012 Aug 15;319(1-2):18-23. doi: 10.1016/j.jns.2012.05.036. Epub 2012 Jun 5.

PMID:
22676847
18.

Upregulation of TRAIL expression on human T lymphocytes by interferon beta and glatiramer acetate.

Arbour N, Rastikerdar E, McCrea E, Lapierre Y, Dörr J, Bar-Or A, Antel JP.

Mult Scler. 2005 Dec;11(6):652-7.

PMID:
16320724
19.

Remitting-relapsing multiple sclerosis patient refractory to conventional treatments and bone marrow transplantation who responded to natalizumab.

Mouzaki A, Koutsokera M, Dervilli Z, Rodi M, Kalavrizioti D, Dimisianos N, Matsoukas I, Papathanasopoulos P.

Int J Gen Med. 2010 Oct 5;3:313-20. doi: 10.2147/IJGM.S13648.

20.

Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.

Venken K, Hellings N, Hensen K, Rummens JL, Medaer R, D'hooghe MB, Dubois B, Raus J, Stinissen P.

J Neurosci Res. 2006 Jun;83(8):1432-46.

PMID:
16583400

Supplemental Content

Support Center